{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T01:13:05Z","timestamp":1784077985602,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ijidonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ijid.2017.01.019","type":"journal-article","created":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T13:49:01Z","timestamp":1485352141000},"page":"27-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5057-901X","authenticated-orcid":false,"given":"Samia","family":"Arshad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanthida","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary B.","family":"Perri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus J.","family":"Zervos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2017.01.019_bib0005","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/cir124","article-title":"Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets","volume":"52","author":"Kullar","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.01.019_bib0010","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1001\/jama.298.15.1763","article-title":"Invasive methicillin-resistant Staphylococcus aureus infections in the United States","volume":"298","author":"Klevens","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2017.01.019_bib0015","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.01.019_bib0020","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.01.019_bib0025","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2017.01.019_bib0030","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/cir935","article-title":"The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis","volume":"54","author":"van Hal","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.01.019_bib0035","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/cid\/cir147","article-title":"Ceftaroline a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus","volume":"52","author":"Saravolatz","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.01.019_bib0040","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ijantimicag.2013.07.005","article-title":"Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature","volume":"42","author":"Polenakovik","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2017.01.019_bib0045","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/jac\/dks006","article-title":"Methicillin- resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy","volume":"67","author":"Ho","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2017.01.019_bib0050","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10156-012-0449-9","article-title":"The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients","volume":"19","author":"Lin","year":"2013","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijid.2017.01.019_bib0055","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jac\/dkt009","article-title":"Ceftaroline in the treatment of concomitant methicillin-resistant and daptomycin-non-susceptible Staphylococcus aureus infective endocarditis and osteomyelitis: case report","volume":"68","author":"Jongsma","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2017.01.019_bib0060","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1086\/524667","article-title":"Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Soriano","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.01.019_bib0065","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1086\/375057","article-title":"Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia","volume":"36","author":"Lodise","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.01.019_bib0070","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"10.1016\/j.ijid.2017.01.019_bib0075","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1128\/JCM.01508-06","article-title":"A Multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides","volume":"45","author":"Wootton","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijid.2017.01.019_bib0080","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2017.01.019_bib0085","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/0897190014546114","article-title":"Vancomycin nephrotoxicity: a review","volume":"27","author":"Mergenhagen","year":"2014","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.ijid.2017.01.019_bib0090","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/cir764","article-title":"Daptomycin versus vancomycin for bloodstream infections due to methicillin- resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case\u2014control study","volume":"54","author":"Moore","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.01.019_bib0095","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/cid\/cit112","article-title":"Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1\u2009mg\/l: a matched cohort study","volume":"56","author":"Murray","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.01.019_bib0100","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10096-010-1128-3","article-title":"Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naive patient\u2014a review of the literature","volume":"30","author":"van Hal","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2017.01.019_bib0105","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/cid\/ciu583","article-title":"Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy","volume":"59","author":"Kullar","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.01.019_bib0110","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1128\/AAC.00797-12","article-title":"Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity","volume":"56","author":"Rose","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2017.01.019_bib0115","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10096-008-0692-2","article-title":"Daptomycin resistance and treatment failure following vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE)","volume":"28","author":"Cunha","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2017.01.019_bib0120","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/1745-6215-15-233","article-title":"Vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations: study protocol for a phase IIB randomized controlled trial","volume":"15","author":"Kalimuddin","year":"2014","journal-title":"Trials"},{"key":"10.1016\/j.ijid.2017.01.019_bib0125","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2014.9743","article-title":"Clinical management of Staphylococcus aureus bacteremia: a review","volume":"312","author":"Holland","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2017.01.019_bib0130","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1128\/AAC.02371-13","article-title":"Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy","volume":"58","author":"Casapao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2017.01.019_bib0135","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.2146\/ajhp130474","article-title":"A case of profound neutropenia and agranulocytosis associated with off-label use of ceftaroline","volume":"71","author":"Yam","year":"2014","journal-title":"Am J Health Syst Pharm"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197121730022X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197121730022X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T17:53:40Z","timestamp":1536083620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S120197121730022X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":27,"alternative-id":["S120197121730022X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2017.01.019","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2017.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}